|
| | LMK-235 Basic information |
| Product Name: | LMK-235 | | Synonyms: | N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethyl-benzamide;N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235;LMK-235;CS-1820;LMK235; LMK 235;Benzamide, N-[[6-(hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethyl- | | CAS: | 1418033-25-6 | | MF: | C15H22N2O4 | | MW: | 294.35 | | EINECS: | 808-770-7 | | Product Categories: | Inhibitors | | Mol File: | 1418033-25-6.mol |  |
| | LMK-235 Chemical Properties |
| Melting point | 135-138°C | | density | 1.155±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | pka | 9.46±0.20(Predicted) | | color | white to beige | | InChIKey | VRYZCEONIWEUAV-UHFFFAOYSA-N |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | LMK-235 Usage And Synthesis |
| Description | Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues, which commonly results in chromatin condensation and transcriptional repression. LMK 235 is an HDAC inhibitor that selectively targets HDACs 4 and 5 (IC50s = 12 and 4 nM, respectively) over other HDACs (IC50s = 56, 320, 850, 880, and 1,280 for HDACs 6, 1, 11, 2, and 8, respectively). It displays enhanced cytotoxic effects against human cancer cell lines, compared to SAHA or trichostatin A . LMK 235 and derivatives inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations. | | Uses | LMK 235 is a histone deacetylase (HDAC)4 and HDAC5 inhibitor and has shown to have enhanced cytotoxic effects against the human cancer cell lines A2780, Cal27, Kyse510, and MDA-MB231. | | Biochem/physiol Actions | LMK-235 induces the differentiation of odontoblasts in dental pulp cells. It plays an important role in the regeneration of dental tissue. |
| | LMK-235 Preparation Products And Raw materials |
|
